Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MHRA Advise on LABAs

The Medicines and Healthcare products Regulatory Authority has released a safety message on Long-Acting Beta-2 Agonists (LABAs) following concerns in America.

As previously reported, the results of the SMART Study have raised concerns over the use of LABAs in Asthma in the United States. LABAs can be issued without a steroid in America, however in the UK this would not occur if the BTS Guidelines are followed.

The MHRA message reminds prescribers that:

  • patients given salmeterol or formoterol should always be prescribed an inhaled corticosteroid
  • patients with acutely deteriorating asthma should not be initiated on salmeterol or formoterol
  • patients should be monitored closely during the first 3 months of treatment

Action: Clinicians involved in the treatment of asthma should ensure that they are following the current BTS Guideline. Audits should be conducted to ensure that patients who are prescribed LABAs are also prescribed inhaled steroids.

Share 'MHRA Advise on LABAs' on Email Share 'MHRA Advise on LABAs' on Delicious Share 'MHRA Advise on LABAs' on Digg Share 'MHRA Advise on LABAs' on Facebook Share 'MHRA Advise on LABAs' on Google+ Share 'MHRA Advise on LABAs' on reddit Share 'MHRA Advise on LABAs' on StumbleUpon Share 'MHRA Advise on LABAs' on Twitter

atomic-wealth

No Comments to “MHRA Advise on LABAs”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,523 spam comments.

atomic-wealth
fond-illness
summer